Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
March 21, 2023Business Services
OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …
BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody
March 21, 2023Sales and Marketing
BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple …
First candidate from Nurix-Gilead Sciences collaboration exclusively licensed
March 21, 2023Research and Development
US-based Gilead Sciences and Nurix have announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein …
FDA staff appear to support Biogen’s ALS drug despite limited data
March 21, 2023Medical Communications
It appears that the FDA is inclined to support Biogen’s amyotrophic lateral sclerosis (ALS) drug, tofersen, with documents released on …
FDA approves Surgvision’s Explorer Air II device
March 21, 2023Medical Communications
Medical technology company Surgvision has announced that it has received FDA 510(k) approval for its Explorer Air II device. It …
Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.
March 20, 2023Business Services
Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …
AbbVie shares results from study for new psoriasis therapy
March 20, 2023Research and Development
AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …
QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases
March 20, 2023Research and Development
US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …
AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy
March 20, 2023Medical Communications
AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …
Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis
March 20, 2023Medical Communications
Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …
NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)
March 20, 2023Business Services
MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …
New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing
March 20, 2023Business Services
STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
March 20, 2023Business Services
Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
March 20, 2023Business Services
Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Sun Pharma settles at $75m in industry-wide price-fixing case
March 17, 2023Sales and Marketing
Sun Pharma has decided a settlement of $75m as part of a case surrounding various pharma companies fixing their prices. …
Sanofi to cut insulin prices by 78% starting January 2024
March 17, 2023Sales and Marketing
French pharmaceutical company Sanofi has announced that it will cut the list price of its Lantus (insulin glargine injection) 100 …
FDA approves Novartis’ Tafinlar and Mekinist combination
March 17, 2023Medical Communications
The FDA has approved Novartis’ combination therapy, Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of BRAF V600E low-grade glioma …
CANbridge Pharmaceuticals reports positive long-term data for glioblastoma multiforme drug
March 17, 2023Medical Communications
Chinese biopharmaceutical company CANbridge Pharmaceuticals has announced positive long-term follow-up data from its clinical studies into a glioblastoma multiforme (GBM) …
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer
March 17, 2023Business Services
Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …
Newron to present at the 31st European Congress of Psychiatry
March 17, 2023Business Services
Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …
Latest content
FibroFind appoints Lee Borthwick as CEO
